Shots:

•  In a global P-III combination of BYL719 + fulvestrant improved PFS vs fulvestrant in postmenopausal women and men with (HR+/HER2-) PIK3CA-mutant Breast Cancer that progressed on aromatase inh. ± CDK4/6i
•  In this study (N=572) in ratio 1:1 BYL719 300 mg (P.O.) + fulvestrant 500mg (IM QD) in patients either in PIK3CA-mutant cohort or PIK3CA non-mutant cohort
• Novartis is expected to present complete results in upcoming congress and initiate WW regulatory discussions

/ article | Ref: Novartis | Image: Novartis